These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26562052)

  • 1. Modified intention-to-treat analysis did not bias trial results.
    Dossing A; Tarp S; Furst DE; Gluud C; Wells GA; Beyene J; Hansen BB; Bliddal H; Christensen R
    J Clin Epidemiol; 2016 Apr; 72():66-74. PubMed ID: 26562052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study.
    Abraha I; Cherubini A; Cozzolino F; De Florio R; Luchetta ML; Rimland JM; Folletti I; Marchesi M; Germani A; Orso M; Eusebi P; Montedori A
    BMJ; 2015 May; 350():h2445. PubMed ID: 26016488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews.
    Abraha I; Cozzolino F; Orso M; Marchesi M; Germani A; Lombardo G; Eusebi P; De Florio R; Luchetta ML; Iorio A; Montedori A
    J Clin Epidemiol; 2017 Apr; 84():37-46. PubMed ID: 28088592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study.
    Montedori A; Bonacini MI; Casazza G; Luchetta ML; Duca P; Cozzolino F; Abraha I
    Trials; 2011 Feb; 12():58. PubMed ID: 21356072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intention-to-treat and transparency of related practices in randomized, controlled trials of anti-infectives.
    Beckett RD; Loeser KC; Bowman KR; Towne TG
    BMC Med Res Methodol; 2016 Aug; 16(1):106. PubMed ID: 27557676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.
    Kristensen LE; Jakobsen AK; Bartels EM; Geborek P; Bliddal H; Saxne T; Danneskiold-Samsøe B; Christensen R
    Scand J Rheumatol; 2011 Jan; 40(1):1-7. PubMed ID: 20950126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.
    Choy EH; Smith C; Doré CJ; Scott DL
    Rheumatology (Oxford); 2005 Nov; 44(11):1414-21. PubMed ID: 16030080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpreting trial results following use of different intention-to-treat approaches for preventing attrition bias: a meta-epidemiological study protocol.
    Dossing A; Tarp S; Furst DE; Gluud C; Beyene J; Hansen BB; Bliddal H; Christensen R
    BMJ Open; 2014 Sep; 4(9):e005297. PubMed ID: 25260368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.
    Wassenberg S; Rau R; Steinfeld P; Zeidler H
    Arthritis Rheum; 2005 Nov; 52(11):3371-80. PubMed ID: 16255011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Singh JA; Cameron C; Noorbaloochi S; Cullis T; Tucker M; Christensen R; Ghogomu ET; Coyle D; Clifford T; Tugwell P; Wells GA
    Lancet; 2015 Jul; 386(9990):258-65. PubMed ID: 25975452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.
    Tarp S; Furst DE; Dossing A; Østergaard M; Lorenzen T; Hansen MS; Singh JA; Choy EH; Boers M; Suarez-Almazor ME; Kristensen LE; Bliddal H; Christensen R
    Semin Arthritis Rheum; 2017 Jun; 46(6):699-708. PubMed ID: 27769592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.
    Callhoff J; Weiß A; Zink A; Listing J
    Rheumatology (Oxford); 2013 Dec; 52(12):2127-35. PubMed ID: 23946435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analyzing phase III studies in hospice/palliative care. a solution that sits between intention-to-treat and per protocol analyses: the palliative-modified ITT analysis.
    Currow DC; Plummer JL; Kutner JS; Samsa GP; Abernethy AP
    J Pain Symptom Manage; 2012 Oct; 44(4):595-603. PubMed ID: 22819439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.
    Christensen AW; Tarp S; Furst DE; Døssing A; Amris K; Bliddal H; Taylor PC; Christensen R
    PLoS One; 2015; 10(9):e0136982. PubMed ID: 26360583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomized control trials.
    Mohammed AT; Khattab M; Ahmed AM; Turk T; Sakr N; M Khalil A; Abdelhalim M; Sawaf B; Hirayama K; Huy NT
    Clin Rheumatol; 2017 Dec; 36(12):2697-2707. PubMed ID: 28914373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review finds variable use of the intention-to-treat principle in musculoskeletal randomized controlled trials with missing data.
    Joseph R; Sim J; Ogollah R; Lewis M
    J Clin Epidemiol; 2015 Jan; 68(1):15-24. PubMed ID: 25304501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.